Compugen

NEWS

Apr 17, 2018

Preclinical Data Presented by Bayer at AACR Highlights BAY 1905254, formerly the CGEN-15001T Program, Efficacy in Cancer Immunotherapy

Apr 02, 2018

Compugen Announces Exclusive License Agreement with MedImmune for the Development of Bi-Specific and Multi-Specific Antibody Products

ALL NEWS

DISCOVERY

Holon

Our optimized process for predictive discovery of novel drug targets

DEVELOPMENT

San Francisco

Discovery & development of first-in-class monoclonal antibody therapeutics

Compugen, FROM CODE TO CURE

Our Pipeline

COM701/PVRIG (CGEN-15029)

CGEN-15029 is the internal designation for PVRIG, a novel B7/CD28-like immune checkpoint target candidate discovered by...

COM902/TIGIT (CGEN-15137)

CGEN-15137 is the internal designation for TIGIT, an immune checkpoint in the B7/CD28 family which has recently gained broad...

CGEN-15001T

CGEN-15001T is a novel B7/CD28-like immune checkpoint target candidate discovered by Compugen. CGEN-15001T is expressed in various subpopulations of immune cells...

CGEN-15001

CGEN-15001 is our lead program for autoimmune diseases. It is a first-in-class therapeutic candidate of a novel inhibitory checkpoint pathway, with the potential to restore...

Apr 02, 2018

MedImmune License Agreement

Mar 13, 2018

Compugen Presentation at the Cowen and Company 38th Annual Health Care Conference

Feb 21, 2018

Compugen Fourth Quarter and Full Year 2017 Earnings Conference Call

MORE EVENTS

Collaborations

In August 2013, Compugen entered into a collaboration and license agreement with Bayer HealthCare ...

In March 2018, Compugen entered into an exclusive license agreement with MedImmune, the global biologics research and ...

Click here for more info about partnering with Compugen